The purpose of the study is to evaluate treatment outcomes of breast cancer with internal mammary or supraclavicular lymph node metastasis according to total radiation dose of postoperative radiation therapy differentiated by tumor response to neoadjuvant chemotherapy. The main questions it aims to answer are: * 5-year disease-free survival * 5-year overall survival * 5-year locoregional recurrence * Adverse events after radiation therapy * Quality of life Participants will be assessed by multi-dimensional methods before and after radiotherapy: * Disease status evaluation including physical and radiological examination * Quality of life assessment with questionnaires (BREAST-Q) * Adverse event assessment according to CTCAE version 5.0
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions
Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy
Samsung Medical Center
Seoul, South Korea
RECRUITING5-year disease-free survival
The event for disease-free survival is defined as any disease recurrence or breast cancer-related death
Time frame: 5 years from the initiation of the radiation therapy
5-year overall survival
The event for overall survival is defined as death of patient with any cause.
Time frame: 5 years from the initiation of the radiation therapy
5-year locoregional recurrence
The event for locoregional recurrence is defined as disease recurrence in irradiated breast / chest wall and/or regional lymph node area including internal mammary and supraclavicular lymph node area.
Time frame: 5 years from the initiation of the radiation therapy
Adverse events
Adverse events after radiation therapy is graded according to CTCAE version 5.0.
Time frame: 5 years from the initiation of the radiation therapy
Quality of life (BREAST-Q™)
Quality of life is assessed by BREAST-Q™ questionnaires. Each score from BREAST-Q™ scales ranges from 0 to 100. Higher scores reflect a better outcome except Cancer Worry scale.
Time frame: 5 years from the initiation of the radiation therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.